SG11201501867UA - Novel uses - Google Patents

Novel uses

Info

Publication number
SG11201501867UA
SG11201501867UA SG11201501867UA SG11201501867UA SG11201501867UA SG 11201501867U A SG11201501867U A SG 11201501867UA SG 11201501867U A SG11201501867U A SG 11201501867UA SG 11201501867U A SG11201501867U A SG 11201501867UA SG 11201501867U A SG11201501867U A SG 11201501867UA
Authority
SG
Singapore
Prior art keywords
novel uses
novel
Prior art date
Application number
SG11201501867UA
Other languages
English (en)
Inventor
Ratti Emiliangelo
Trower Michael
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of SG11201501867UA publication Critical patent/SG11201501867UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrically Operated Instructional Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SG11201501867UA 2012-10-11 2013-10-09 Novel uses SG11201501867UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261712499P 2012-10-11 2012-10-11
PCT/EP2013/071093 WO2014057003A1 (en) 2012-10-11 2013-10-09 Novel uses

Publications (1)

Publication Number Publication Date
SG11201501867UA true SG11201501867UA (en) 2015-04-29

Family

ID=49322388

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501867UA SG11201501867UA (en) 2012-10-11 2013-10-09 Novel uses

Country Status (24)

Country Link
US (3) US9603849B2 (lt)
EP (2) EP2906219B1 (lt)
JP (2) JP6815728B2 (lt)
KR (1) KR102202481B1 (lt)
CN (1) CN104703603A (lt)
AU (1) AU2013328695B9 (lt)
BR (1) BR112015006051A2 (lt)
CA (1) CA2884454C (lt)
CY (1) CY1122313T1 (lt)
DK (1) DK2906219T3 (lt)
EA (1) EA201590364A1 (lt)
ES (1) ES2750662T3 (lt)
HK (1) HK1211486A1 (lt)
HR (1) HRP20191955T1 (lt)
HU (1) HUE046508T2 (lt)
IL (1) IL237636B (lt)
LT (1) LT2906219T (lt)
MX (1) MX362879B (lt)
PL (1) PL2906219T3 (lt)
PT (1) PT2906219T (lt)
RS (1) RS59470B1 (lt)
SG (1) SG11201501867UA (lt)
SI (1) SI2906219T1 (lt)
WO (1) WO2014057003A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603849B2 (en) * 2012-10-11 2017-03-28 Nerre Therapeutics Limited Uses of orvepitant
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
SI3377064T1 (sl) * 2016-01-08 2019-11-29 Nerre Therapeutics Ltd Orvepitant za zdravljenje kroničnega kašlja
CN109640981A (zh) * 2016-06-29 2019-04-16 曼隆治疗公司 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途
TWI805601B (zh) 2017-08-11 2023-06-21 南韓商愛茉莉太平洋股份有限公司 醫藥組成物及抑制其形成結晶的方法
WO2021046350A1 (en) * 2019-09-05 2021-03-11 Incyte Corporation Ruxolitinib formulation for reduction of itch in atopic dermatitis
JP7478894B1 (ja) 2022-11-30 2024-05-07 花王株式会社 痒みの予防又は改善剤
JP7478895B1 (ja) 2022-11-30 2024-05-07 花王株式会社 痒みの予防又は改善剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2728265A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
EP1295599A1 (en) 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Method for the treatment of prevention of atopic dermatitis
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
EP1594574A2 (en) * 2003-01-27 2005-11-16 Glaxo Group Limited Nk1 receptor antagonists for the treatment of functional dyspepsia
GB0522061D0 (en) 2005-10-28 2005-12-07 Glaxo Group Ltd Chemical process
CN101970488B (zh) * 2007-12-07 2014-06-18 津莫吉尼蒂克斯公司 对il-31特异的人源化抗体分子
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
BRPI1008008A2 (pt) * 2009-02-24 2016-02-23 Novartis Ag usos de antagonistas do receptor de nk
WO2012121988A2 (en) * 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
RU2631319C2 (ru) 2012-02-22 2017-09-21 Лео Фарма А/С Новые соединения - антагонисты рецептора нейрокинина 1
US9603849B2 (en) * 2012-10-11 2017-03-28 Nerre Therapeutics Limited Uses of orvepitant
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus

Also Published As

Publication number Publication date
CN104703603A (zh) 2015-06-10
MX362879B (es) 2019-02-21
US20150238486A1 (en) 2015-08-27
AU2013328695B2 (en) 2018-04-05
EP2906219A1 (en) 2015-08-19
ES2750662T3 (es) 2020-03-26
EP2906219B1 (en) 2019-08-07
RS59470B1 (sr) 2019-11-29
US20190216806A1 (en) 2019-07-18
AU2013328695A9 (en) 2018-04-26
HK1211486A1 (en) 2016-05-27
SI2906219T1 (sl) 2019-12-31
AU2013328695A1 (en) 2015-04-02
JP6953468B2 (ja) 2021-10-27
KR20150064732A (ko) 2015-06-11
CY1122313T1 (el) 2021-01-27
IL237636B (en) 2019-01-31
HUE046508T2 (hu) 2020-03-30
DK2906219T3 (da) 2019-10-28
JP2019131594A (ja) 2019-08-08
PL2906219T3 (pl) 2020-02-28
PT2906219T (pt) 2019-11-04
CA2884454A1 (en) 2014-04-17
LT2906219T (lt) 2019-10-25
EA201590364A1 (ru) 2015-11-30
US20170143711A1 (en) 2017-05-25
AU2013328695B9 (en) 2018-05-17
CA2884454C (en) 2021-07-27
JP2015533136A (ja) 2015-11-19
IL237636A0 (en) 2015-04-30
JP6815728B2 (ja) 2021-01-20
BR112015006051A2 (pt) 2017-07-04
EP3597192A1 (en) 2020-01-22
HRP20191955T1 (hr) 2020-01-24
WO2014057003A1 (en) 2014-04-17
KR102202481B1 (ko) 2021-01-12
US9603849B2 (en) 2017-03-28
MX2015004162A (es) 2015-07-06

Similar Documents

Publication Publication Date Title
DK3327112T3 (en) Agse-deficient stamme
EP2754580A4 (en) DUMP TRUCK
DK2830816T3 (en) Hidtil ukendt coatingkoncept
HK1204797A1 (en) Novel anti-siglec15 antibody -siglec-15
EP2935220A4 (en) PERI-carbinol
HK1211486A1 (en) Novel uses
GB201216800D0 (en) Novel use
EP2920142A4 (en) MÉTHANOFULLERRÈNES
EP2812698A4 (en) TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR
ZA201409022B (en) 3-o-heteroaryl-ingenol
EP2920157A4 (en) DI MACRO CYCLEN
EP2873363A4 (en) DIOPSIMETER
EP2834250A4 (de) Lithiumsilikate
GB201201720D0 (en) Novel combinations
GB201203307D0 (en) Remvox
GB201222528D0 (en) Novel uses
GB201222391D0 (en) Novel Uses
GB201212393D0 (en) Novel combination
GB201207154D0 (en) Novel form
GB201221267D0 (en) Totto
AU345893S (en) Treehouse
GB201212463D0 (en) Novel use
GB201211392D0 (en) 3Tattoo Aplicator
GB201202256D0 (en) Novel use
GB201203507D0 (en) Keynut